Vaginal Dinoprostone in Reducing Pain Perception During Diagnostic Office Hysteroscopy in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial

J Minim Invasive Gynecol. 2020 May-Jun;27(4):847-853. doi: 10.1016/j.jmig.2019.07.026. Epub 2019 Aug 1.

Abstract

Study objective: To evaluate the efficacy of vaginal dinoprostone in reducing pain perception during diagnostic office hysteroscopy (OH) in postmenopausal women.

Design: Randomized, double-blind controlled trial.

Setting: Tertiary university hospital.

Participants: Postmenopausal patients scheduled for OH.

Interventions: Eligible participants were randomized in a 1:1 ratio to the dinoprostone and placebo groups. The severity of pain was assessed with a visual analog scale (VAS) ranging from 0, no pain to 10, worst pain during OH and 30 minutes after OH.

Measurements and main results: The difference in the intensity of pain using the VAS score during the procedure. One hundred women (50 in each arm) were included in the study. The mean VAS score during OH was significantly lower in the dinoprostone group compared with the placebo group (3.9 ± 0.8 vs 5.6 ± 0.7; p <.001). The passage of the hysteroscope through the cervical canal was easier in the dinoprostone group (62.4 ± 9.5 vs 42.8 ± 10.8; p <.001). The 2 groups were comparable in terms of the duration of the procedure (p = .91) and the rate of adverse effects.

Conclusion: Vaginal dinoprostone is effective in relieving pain during diagnostic OH in postmenopausal women with few adverse effects.

Keywords: Dinoprostone; Office hysteroscopy; Pain relief; Prostaglandins.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Dinoprostone / therapeutic use
  • Double-Blind Method
  • Female
  • Humans
  • Hysteroscopy* / adverse effects
  • Hysteroscopy* / methods
  • Misoprostol*
  • Pain / etiology
  • Pain Perception
  • Postmenopause
  • Pregnancy

Substances

  • Misoprostol
  • Dinoprostone